These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 32115865)

  • 1. Laboratory testing in hemophilia: Impact of factor and non-factor replacement therapy on coagulation assays.
    Peyvandi F; Kenet G; Pekrul I; Pruthi RK; Ramge P; Spannagl M
    J Thromb Haemost; 2020 Jun; 18(6):1242-1255. PubMed ID: 32115865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor VIII and IX assays for post-infusion monitoring in hemophilia patients: Guidelines from the French BIMHO group (GFHT).
    Jeanpierre E; Pouplard C; Lasne D; Le Cam Duchez V; Eschwege V; Flaujac C; Galinat H; Harzallah I; Proulle V; Smahi M; Sobas F; Stepina N; Toulon P; Voisin S; Ternisien C; Nougier C;
    Eur J Haematol; 2020 Aug; 105(2):103-115. PubMed ID: 32277501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays.
    Kitchen S; Blakemore J; Friedman KD; Hart DP; Ko RH; Perry D; Platton S; Tan-Castillo D; Young G; Luddington RJ
    J Thromb Haemost; 2016 Apr; 14(4):757-64. PubMed ID: 26748742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments.
    Bowyer AE; Gosselin RC
    Semin Thromb Hemost; 2023 Sep; 49(6):609-620. PubMed ID: 36473488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New challenges and best practices for the laboratory monitoring of factor VIII and factor IX replacement.
    Van den Bossche D; Peerlinck K; Jacquemin M
    Int J Lab Hematol; 2018 May; 40 Suppl 1():21-29. PubMed ID: 29741261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B.
    Marlar RA; Strandberg K; Shima M; Adcock DM
    Eur J Haematol; 2020 Jan; 104(1):3-14. PubMed ID: 31606899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Review of Factor VIII and Factor IX Assay Methods for Monitoring Extended Half-Life Products in Hemophilia A and B.
    Abraham S; Duncan EM
    Methods Mol Biol; 2023; 2663():569-588. PubMed ID: 37204737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma Clearance of Coagulation Factor VIII and Extension of Its Half-Life for the Therapy of Hemophilia A: A Critical Review of the Current State of Research and Practice.
    Sarafanov AG
    Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measuring factor IX activity of nonacog beta pegol with commercially available one-stage clotting and chromogenic assay kits: a two-center study.
    Bowyer AE; Hillarp A; Ezban M; Persson P; Kitchen S
    J Thromb Haemost; 2016 Jul; 14(7):1428-35. PubMed ID: 27107268
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol.
    Tiefenbacher S; Bohra R; Amiral J; Bowyer A; Kitchen S; Lochu A; Rosén S; Ezban M
    J Thromb Haemost; 2017 Oct; 15(10):1901-1912. PubMed ID: 28772338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor Activity Assays for Monitoring Extended Half-Life FVIII and Factor IX Replacement Therapies.
    Kitchen S; Tiefenbacher S; Gosselin R
    Semin Thromb Hemost; 2017 Apr; 43(3):331-337. PubMed ID: 28264199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment patterns and bleeding outcomes in persons with severe hemophilia A and B in a real-world setting.
    Ay C; Perschy L; Rejtö J; Kaider A; Pabinger I
    Ann Hematol; 2020 Dec; 99(12):2763-2771. PubMed ID: 32918114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of chromogenic assays in haemophilia A and B diagnosis.
    Bowyer AE; Duncan EM; Antovic JP
    Haemophilia; 2018 Jul; 24(4):578-583. PubMed ID: 29808946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The evolution of recombinant factor replacement for hemophilia.
    Sankar AD; Weyand AC; Pipe SW
    Transfus Apher Sci; 2019 Oct; 58(5):596-600. PubMed ID: 31421983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress, and prospects in the therapeutic armamentarium of persons with congenital hemophilia. Defining the place for liver-directed gene therapy.
    Di Minno G; Castaman G; De Cristofaro R; Brunetti-Pierri N; Pastore L; Castaldo G; Trama U; Di Minno M
    Blood Rev; 2023 Mar; 58():101011. PubMed ID: 36031462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Considerations on activity assay discrepancies in factor VIII and factor IX products.
    Ovanesov MV; Jackson JW; Golding B; Lee TK
    J Thromb Haemost; 2021 Sep; 19(9):2102-2111. PubMed ID: 34145730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis and prediction of long-term durability of factor IX activity following etranacogene dezaparvovec gene therapy in the treatment of hemophilia B.
    Shah J; Kim H; Sivamurthy K; Monahan PE; Fries M
    Curr Med Res Opin; 2023 Feb; 39(2):227-237. PubMed ID: 36285399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Update on Laboratory Diagnostics in Haemophilia A and B.
    Müller J; Miesbach W; Prüller F; Siegemund T; Scholz U; Sachs UJ;
    Hamostaseologie; 2022 Aug; 42(4):248-260. PubMed ID: 35104901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management.
    Müller J; Goldmann G; Marquardt N; Pötzsch B; Oldenburg J
    Hamostaseologie; 2020 Nov; 40(S 01):S15-S20. PubMed ID: 33187006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advances in surgery and its perioperative treatment in people with hemophilia.
    Rodríguez-Merchán EC
    Expert Rev Hematol; 2021 Mar; 14(3):271-280. PubMed ID: 33605827
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 23.